News
China NMPA accepts and grants priority review status to ArkBio's NDA for Azstarys to treat ADHD in patients aged six years and above: Shanghai, China Tuesday, June 17, 2025, 10:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback